TY  - JOUR
AB  - The authors of this article published in Diabetes and Metabolism (https://doi.org/10.1016/j.diabet.2017.12.007) wish it to be known that their full affiliations are as given above.
AU  - Capristo, E.*
AU  - Panunzi, S.*
AU  - De Gaetano, A.*
AU  - Raffaelli, M.*
AU  - Guidone, C.*
AU  - Iaconelli, A.*
AU  - L'Abbate, L.*
AU  - Birkenfeld, A.L.
AU  - Bellantone, R.*
AU  - Bornstein, S.*
AU  - Mingrone, G.*
C1  - 55658
C2  - 46507
CY  - 21 Street Camille Desmoulins, Issy, 92789 Moulineaux Cedex 9, France
SP  - 179-179
TI  - Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study (vol 44, pg 235, 2018).
JO  - Diabetes Metab.
VL  - 19
IS  - 2
PB  - Masson Editeur
PY  - 2020
SN  - 1262-3636
ER  - 

TY  - JOUR
AB  - Background/Objectives. - As only 1% of clinically eligible subjects choose to undergo surgical treatment for obesity, other options should be investigated. This study aimed to assess the effects of intensive lifestyle modification (ILM) with or without 3-mg liraglutide daily vs. sleeve gastrectomy (SG) on BMI after 1 year.Subjects/methods. - In this study performed at an Italian university hospital, non-diabetic patients eligible for bariatric surgery were recruited from a weight-loss clinic and had the option to choose from three possible weight-loss programmes up to an allocation of 25 subjects in each arm matched by Bil and age. ILM consisted in 813 kcal of a very low-calorie diet (VLCD) for 1 month, followed by a diet of 12 kcal/kg body weight of high protein and high fat for 11 months plus 30 min of brisk walking daily and at least 3 h of aerobic exercise weekly. SG patients followed a VLCD for 1 month and a free diet thereafter. Patients were evaluated at baseline and at 1, 3, 6, 9 and 12 months.Results. - A total of 75 patients were enrolled; retention was 100% in the SG and 85% in the two medical arms. SG reduced BMI by 32% (P < 0.001 vs. medical arm), while ILM + liraglutide and ILM led to BMI reductions of 24% and 14%, respectively (P < 0.001). More women allocated themselves to the ILM + liraglutide group. Weight loss was 43 kg with SG, 26 kg with ILM + liraglutide and 15 kg with ILM alone. Lean body mass reductions were -11.6 kg with SG, -6.3 kg with ILM and -8.3 kg with ILM + liraglutide. Prevalence of prediabetes was significantly lower with ILM + liraglutide, and insulin resistance was reduced by about 70% by both ILM + liraglutide and SG vs. 39% by ILM alone. Cardiometabolic risk factors were greatly reduced in all three groups.Discussion. - At least in the short-term, liraglutide 3.0 mg once daily associated with drastic calorie- intake restriction and intensive physical activity promoted a 24% weight loss, which was almost two times greater than ILM alone and only about 25% less than with SG, while preserving lean body mass. Although this study was non-randomised, it was designed to explore the efficacy of medical treatments for obesity in everyday clinical practice.
AU  - Capristo, E.*
AU  - Panunzi, S.*
AU  - De Gaetano, A.*
AU  - Raffaelli, M.*
AU  - Guidone, C.*
AU  - Iaconelli, A.*
AU  - L'Abbate, L.*
AU  - Birkenfeld, A.L.
AU  - Bellantone, R.*
AU  - Bornstein, S.R.*
AU  - Mingrone, G.*
C1  - 52881
C2  - 44203
CY  - 21 Street Camille Desmoulins, Issy, 92789 Moulineaux Cedex 9, France
SP  - 235-242
TI  - Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study.
JO  - Diabetes Metab.
VL  - 44
IS  - 3
PB  - Masson Editeur
PY  - 2017
SN  - 1262-3636
ER  - 

TY  - JOUR
AB  - Background. In clinical practice, there is a strong interest in non-invasive markers of non-alcoholic fatty liver disease (NAFLD). Our hypothesis was that the fold-change in plasma triglycerides (TG) during a 2-h oral glucose tolerance test (fold-change TG(OGTT)) in concert with blood glucose and lipid parameters, and the rs738409 C > G single nucleotide polymorphism (SNP) in PNPLA3 might improve the power of the widely used fatty liver index (FLI) to predict NAFLD. Methods. The liver fat content of 330 subjects was quantified by H-1-magnetic resonance spectroscopy. Blood parameters were measured during fasting and after a 2-h OGTT. A subgroup of 213 subjects underwent these measurements before and after 9 months of a lifestyle intervention. Results. The fold-change TG(OGTT) was closely associated with liver fat content (r=0.51, P < 0.0001), but had less power to predict NAFLD (AUROC = 0.75) than the FLI (AUROC = 0.79). Not only was the fold-change TG(OGTT) independently associated with liver fat content and NAFLD, but so also were the 2-h blood glucose level and rs738409 C>G SNP in PNPLA3. In fact, a novel index (extended FLI) generated from these and the usual FLI parameters considerably increased its power to predict NAFLD (AUROC = 0.79-0.86). The extended FLI also increased the power to predict changes in liver fat content with a lifestyle intervention (n = 213; standardized beta coefficient: 0.23-0.29). Conclusion. This study has provided novel data confirming that the OGTT-derived fold-change TG(OGTT) and 2-h glucose level, together with the rs738409 C>G SNP in PNPLA3, allow calculation of an extended FLI that considerably improves its power to predict NAFLD. (C) 2017 Elsevier Masson SAS. All rights reserved.
AU  - Kantartzis, K.
AU  - Rettig, I.*
AU  - Staiger, H.
AU  - Machann, J.
AU  - Schick, F.
AU  - Scheja, L.*
AU  - Gastaldelli, A.*
AU  - Bugianesi, E.*
AU  - Peter, A.
AU  - Schulze, M.B.
AU  - Fritsche, A.
AU  - Häring, H.-U.
AU  - Stefan, N.
C1  - 51556
C2  - 43244
CY  - Moulineaux Cedex 9
SP  - 229-239
TI  - An extended fatty liver index to predict non-alcoholic fatty liver disease.
JO  - Diabetes Metab.
VL  - 43
IS  - 3
PB  - Masson Editeur
PY  - 2017
SN  - 1262-3636
ER  -